Alireza Pouramini
1 
, Maryam Khosravian
2 , Fatemeh Kafi
1 , Sina Bakhshaei
3,4 , Hamid Reza Jahantigh
5 , Payam Peymani
6 , Neda Kianpour
7 , Majid Foroutan
8* 1 Nickan Research Institute, Isfahan, Iran
2 Department of Internal Medicine I, Martin Luther University, Halle, Germany
3 Temecula Valley Hospital, Temecula, California, USA
4 UHS SoCal MEC (Universal Health Service Southern California Medical Education Consortium), Internal Medicine Residency Program, Temecula, California, USA
5 Animal Health and Zoonosis PhD Course, Department of Veterinary Medicine, University of Bari, Bari, Italy
6 College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada
7 Department of Biotechnology, Inland Norway University of Applied Science, Hamar, Hedmark, Norway
8 Department of Internal Medicine, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran
Implication for health policy/practice/research/medical education:
Paxlovid is an effective oral treatment for COVID-19 patients that reduces mortality and can be administered in an outpatient setting, but it cannot substitute COVID-19 immunizations.
Please cite this paper as: Pouramini A, Khosravian M, Kafi F, Bakhshaei S, Jahantigh HR, Kianpour N. Foroutan M. Hope and fear; Paxlovid for COVID-19 treatment: A Letter to the Editor. J Nephropharmacol. 2022;11(2):e10485. DOI: 10.34172/npj.2022.10485.